Prosecution Insights
Last updated: November 12, 2026
Application No. 18/836,248

IMMUNOGENIC MRNA DELIVERY VEHICLES

Non-Final OA §103§112§DOUBLEPATENT
Filed
Aug 06, 2024
Priority
Feb 07, 2022 — provisional 63/307,578 +1 more
Examiner
STEVENS, MARK V
Art Unit
1613
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Corner Therapeutics Inc.
OA Round
1 (Non-Final)
65%
Grant Probability
Favorable
1-2
OA Rounds
99%
With Interview

Examiner Intelligence

Grants 65% — above average
65%
Career Allowance Rate
575 granted / 879 resolved
+5.4% vs TC avg
Strong +42% interview lift
Without
With
+41.6%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
49 currently pending
Career history
950
Total Applications
across all art units

Office Action

§103 §112 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Status Claims 3-5, 14-17, 20-21, 23-24, 29, 31-41, 51-57, and 59-62 are cancelled. Claims 1, 2, 6-13, 18, 19, 22, 25-28, 30, 42-50, 58, and 63-66 are pending. Claims 43-50 and 63-66 are withdrawn. Claims 1, 2, 6-13, 18, 19, 22, 25-28, 30, 42, and 58 are under examination. Priority This application is a national stage entry of PCT/US2023/062063 filed on 2/6/2023, which claims priority to US provisional application 63/307,578 filed on 2/7/2022. Information Disclosure Statement The information disclosure statements filed on 04/22/2025 and 08/19/2026 have been considered by the examiner. Election/Restrictions Applicant’s election without traverse of Group I (claims 1, 2, 6-13, 18, 19, 22, 25-28, 30, 42, and 58) in the reply filed on 8/19/2026 is acknowledged. Claims 43-50 and 63-66 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected inventions, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 8/19/2026. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 7-13, and 18-19 rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 6 is indefinite for the recitation of “the at least one lipid comprises…” as it makes it unclear if the at least one lipid of claim 1, which claim 6 depends on, is now open to other lipids since claim 1 first presented a closed Markush group of items for “at least one lipid”. Applicant may amend this claim to indicate “the at least one lipid is…..” Claims 7-13 are rejected as being dependent on an indefinite claim. Claim 7 is indefinite for the recitation of “the ionizable lipid comprises…” as it makes it unclear if the at least one lipid of claim 1, which claim 6 depends on, is now open to other lipids since claim 1 first presented a closed Markush group of items for “at least one lipid”. Note that ionizable lipid is within the closed group. Applicant may amend this claim to indicate “the ionizable lipid is…..” Claim 7 is indefinite for “or analogs or derivatives thereof” as it is not indicated what types of analogs or derivations would be referred to, which could encompass compounds with numerous different structures and/or functions. Thus, it is unclear what the metes and bounds of the claim limitations are with use of analogs or derivatives thereof. Applicant may consider deleting “or analogs or derivatives thereof” in this claim. Claim 9 is indefinite for the recitation of “the pegylated lipid comprises…” as it makes it unclear if the at least one lipid of claim 1, which claim 6 depends on, is now open to other lipids since claim 1 first presented a closed Markush group of items for “at least one lipid”. Note that pegylated lipid is within the closed group. Applicant may amend this claim to indicate “the pegylated lipid is…..” Claim 11 is indefinite for the recitation of “the structural lipid comprises…” as it makes it unclear if the at least one lipid of claim 1, which claim 6 depends on, is now open to other lipids since claim 1 first presented a closed Markush group of items for “at least one lipid”. Note that structural lipid is within the closed group. Applicant may amend this claim to indicate “the structural lipid is…..” Claim 12 is indefinite for the recitation of “the second phosholipid comprises…” as it makes it unclear if the at least one lipid of claim 1, which claim 6 depends on, is now open to other lipids since claim 1 first presented a closed Markush group of items for “at least one lipid”. Note that second phospholipid is within the closed group. Applicant may amend this claim to indicate “the second phospholipid is…..” Claim 18 is indefinite for the use of “mRNA complexed with one or more lipids (RNA-Lipoplex) as it is unclear if what should be considered is any RNA based on the parenthetical of RNA-lipoplex or the mRNA, more particularly, as provided outside the parenthetical. Applicant may delete the parenthetical recitation. Claim 19 is rejected as being dependent on an indefinite claim. Claim Rejections – 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1, 2, 6-13, 18, 19, 22, 25-28, 30, 42 and 58 are rejected under 35 U.S.C. 103 as being unpatentable over Buschmann US 2022/0218622 (effective filing date of 10-13-2021 and 10-14-2020 based on filing date and priority filing) and Choung US20160022711. Buschmann teaches ionizable lipids for use in lipid nanoparticles that are useful for delivery mRNA the can encode vaccines for treatment of infectious diseases or cancers (abstract and claim 1). Buschmann teaches antigen-providing mRNA (paragraphs 183 and 2619). Buschmann teaches “As used herein, the term “antigen-providing mRNA” in the context of the invention may typically be an mRNA, having at least one open reading frame that can be translated by a cell or an organism provided with that mRNA” (paragraphs 183 and 2211). Buschmann teaches a mRNA sequence encoding at least one antigenic peptide or protein, and DSPC, cholesterol and a PEG lipid at a ratio of about 50:10:38.5:1 (paragraph 2248). Buschmann teaches ionizable lipids that have adjuvant effect (paragraph 2589). Buschmann teaches adjuvants for the formulations including lysolecithin (aka lysophosphatidylcholine) and the TLR7/8 agonist (resiquimod) (paragraph 2590). Buschmann teaches stabilizing lipids (paragraph 2222) and ionizable lipids (paragraph 2217). Buschmann teaches “ Lipids of the Invention (as defined herein) combined with other lipid components, such as neutral lipids, steroids, PEG, PEGylated lipids, and oligonucleotides have been used to block degradation of the RNAs in plasma and facilitate the cellular uptake of the oligonucleotides.” (paragraph 9). Buschmann teaches “LNP driven adjuvant effects motivates the identification of structure function relationships (SFRs) controlling these properties which may involve the cyclic vs linear nature of the headgroups” (paragraph 2185). Thus, Buschmann provides for the teachings that would allow one to produce such a lipid nanoparticle that has adjuvant ionizable lipids, structural lipids and other lipids, and contains mRNA to encode for vaccine antigens, the lipid adjuvant lysolecithin (lysophosphatidylcholine) and a TLR7/8 agonist as another adjuvant. The adjuvants are seen in Buschmann to help such formulations by enhancing efficacy of agents such as the vaccine (paragraph 176). Buschmann teaches “PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramides (e.g., PEG-CerC14 or PEG-CerC20), PEG-modified dialkylamines, PEG-modified diacylglycerols, PEG-modified dialkylglycerols” (paragraph 2230). Buschmann teaches cholesterol (paragraphs 2248, 2250 and 2272). Buschmann teaches 1,2-distearoyl-sn-glycero-3-phosphocholine (18:0 PC, DSPC) (paragraphs 2223 and 2777; also provides for DOPC and others). Buschmann teaches a composition with a pharmaceutical carrier and/or excipient (paragraph 196). Buschmann teaches sphingomyelins among neutral lipids (paragraph 2222). Buschmann teaches DMG-PEG (mw 2000) (paragraphs 2776 and 2792). Buschmann teaches SM-102 and ALC-0315 (see table 11b regarding exemplary ionizable lipids). Although Buschmann allows for lysolecithin/lysophosphatidylcholine in its formulations, it does not provide for the acyl chain lengths. Choung teaches a lipid nanomaterial containing lysophosphatidylcholine or an ether derivative thereof (abstract) that is used for treating subjects. Choung teaches the lysophosphatidylcholine represented by chemical formula 1 is selected from the group consisting of L-α-lysophosphatidylcholine, stearoyl; L-α-lysophosphatidylcholine, myristoyl; L-α-lysophosphatidylcholine, palmitoyl; DL-α-lysophosphatidylcholine, palmitoyl; and L-α-lysophosphatidylcholine, oleoyl (paragraph 28). Paragraph 27 indicates the R1 group can be 4-30 carbons (alkyl or alkenyl). Stearoyl is an 18 carbon chain acyl chain, myristoyl is a 14 carbon acyl chain, and palmitoyl is a 16 carbon acyl chain. Choung teaches lipid nanomaterial particles (paragraph 68) and lipid nanoparticles with LPC 18:0 (paragraphs 83-86). Choung teaches “To lysophosphatidylcholine (LPC 18:0, NOF) 5.00 g, egg lecithin (Lipoid E-80) 15.00 g, soybean oil 5.00 g, sucrose 50.00 g, EDTA2Na2H2O 27.5 mg, and middle chain triglyceride (Miglyol 812) 5.00 g was added purified water, to make a total weight of 500 g” (paragraph 81). Choung recognizes solving the issue of low solubility of lysophosphatidylcholine involved making lipid nanomaterial forms (paragraph 5). Note making lipid nanoparticles is also an objective of Buschmann. One of ordinary skill in the art before the time of filing would have included lysophosphatidylcholine/lysolecithin of Choung into formulations taught by Buschmann as these are lysophosphatidylcholines recognizes with pharmaceutical benefits and usable with other lipids in producing lipid nanoparticle structures. Thus, there was a reasonable expectation of success in using the lysophosphatidylcholine compounds of Choung in making compositions by teachings of Buschmann and obtaining suitable lipid nanoparticles that deliver the antigen expressing mRNA along with TLR 7/8 agonist that can be used for treatment of a subject with such lipid nanoparticles. Non-Statutory Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1, 2, 6-13, 18, 19, 22, 25-28, 30, 42 and 58 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 2, 8, 9, 11, 13-16, and 36 and claims 103-105, 107 and 109 of copending Application No. 18/836,260 in view of Buschmann US 2022/0218622 (effective filing date of 10-13-2021 and 10-14-2020 based on filing date and priority filing). The claims of ‘260 and applicant’s claims overlap with the exception of the mRNA encoding for an antigen. Buschmann teaches including an mRNA encoding for an antigen to treat cancer or an infectious disease in a lipid nanoparticle formulation. Therefore, one of ordinary skill in the art would have included mRNA that encodes for antigens in teachings of Buschmann to get effective formulation to treat a subject with cancer or an infectious disease. This is a provisional nonstatutory double patenting rejection. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MARK V STEVENS whose telephone number is (571)270-7080. The examiner can normally be reached M-F 9:00 am to 6:00 pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Brian-Yong Kwon can be reached on (571)272-0581. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MARK V STEVENS/Primary Examiner, Art Unit 1613
Read full office action

Prosecution Timeline

Aug 06, 2024
Application Filed
Oct 19, 2026
Non-Final Rejection mailed — §103, §112, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778890
DEVELOPMENT OF A NEW FAMILY OF NANOCARRIERS DERIVED FROM NATURAL TETRAMERIC ACID LIPIDS
2y 5m to grant Granted Nov 03, 2026
Patent 12765573
SOFT CANDY WITHOUT FISHY TASTE OR ODOR AND PREPARATION METHOD THEREOF
2y 11m to grant Granted Oct 20, 2026
Patent 12751917
HYDROGELS AS ORAL DELIVERY DOSAGE FORMS, METHODS OF MAKING AND USING SAME
6y 1m to grant Granted Oct 06, 2026
Patent 12751959
CANNABIDIOL NANODRUG FORMULATIONS AND METHODS FOR USE OF THE SAME
3y 4m to grant Granted Oct 06, 2026
Patent 12751928
PROLONGED-RELEASE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF SULTIAME
2y 11m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
65%
Grant Probability
99%
With Interview (+41.6%)
Low
PTA Risk
Based on 879 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month